Association of COX-2 Promoter Polymorphisms -765G/C and -1195A/G with Migraine
,
Abstract
Background: Migraine is a common debilitating primary headache disorder with current head pain attacks, which contributes to physical activity dysfunctions in chronic pain phase. PGE2 and PGI2 are two important prostaglandins synthesised by COX-2 enzymes, involved in migraine pain signals. COX-2 modulation is essential in treatment and pathogenesis of migraine. This study aimed to investigating the association between COX-2 gene polymorphisms with the risk of migraine susceptibility in migraine patients with related and unrelated parents.
Methods: This case- control study was based on 100 migraine patients and 100 non-migraine subjects in Bushehr province, Iran in 2013. Genomic DNA of blood samples was extracted and genotyping of COX-2-765G>C (rs20417) and COX-2-1195A>G (rs689466) gene variants was investigated by PCR-RFLP method. Statistical analyses were accomplished using the SPSS software package.
Results: There was a significant differences in the frequencies of the COX-2-765G>C and COX-2-1195A>G genotypes between migraine patients and controls (P≤0.05).
Conclusion: COX-2-765CC, COX-2-765CG, COX-2-1195GG and COX-2-1195AG genotypes can increase the risk of migraine significantly. As the first study in Iran, we are hopeful to achieve greater results about the relevancy of COX-2 gene, migraine and pain signals pathway by repeating these experiments on more samples.
Evans RW (2009). Migraine: a question and answer review. Med Clin North Am, 93(2): 245–62.
Dasdemir S, Cetinkaya Y, Gencer M, Ozkok E, Aydin M, Cakmakoglu B (2013). Cox-2 gene variants in migraine. Gene, 518(2):292–5.
Griffiths LR, Nyholt DR, Curtain RP, Goadsby PJ, Brimage PJ (1997). Migraine association and linkage studies of an endothelial nitric oxide synthase (NOS3) gene polymorphism. Neurology, 49(2):614–7.
Wessman M, Kallela M, Kaunisto MA et al. (2002). A susceptibility locus for migraine with aura, on chromosome 4q24. Am J Hum Genet, 70(3):652–62.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5):343–9.
Lipton RB, Silberstein SD, Stewart WF (1994). An update on the epidemiology of migraine. Headache, 34(6):319–28.
Colson NJ, Lea RA, Quinlan S, Griffiths LR (2006). No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility. BMC Med Genet, 7(1):12.
Schürks M (2012). Genetics of migraine in the age of genome-wide association studies. J Headache Pain, 13(1):1–9.
Menon S (2011). Migraine Molecular Genetic and Pharmacogenetic Studies. Griffith Australia.
Wilkinson M, Blau JN (1985). Are Classical and Common Migraine Different Entities? Headache, 25(4):211–3.
Todt U, Dichgans M, Jurkat-Rott K, Heinze A, Zifarelli G, Koenderink JB, Goebel I, Zumbroich V, Stiller A, Ramirez A, Friedrich T, Göbel H, Kubisch C (2005). Rare missense variants in ATP1A2 in families with clustering of common forms of migraine. Hum Mutat, 26(4):315–21.
Lopez-Campos JL, Rodriguez-Rodriguez D, Rodriguez-Becerra E et al. (2009). Cyclooxygenase-2 polymorphisms confer susceptibility to sarcoidosis but are not related to prognosis. Respir Med, 103(3):427–33.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ (2001). Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature, 410(6827):471–5.
Sambrook J, Russell DW (2001). Molecular Cloning: A Laboratory Manual [Internet]. 3rd ed. New York: Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York; 2001. 1-2100 p.
Shi YY, He L (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2): 97–8.
Ulrich CM, Bigler J, Sibert J, et al. (2002). Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat, 20(5):409–10.
Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar FF, Lin D (2005). Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 129(2):565–76.
Sanak M, Szczeklik W, Szczeklik A (2005). Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol, 116(1):221–3.
Azzam OA, Kadry DM, Rashed LA, El-Refaie AEA, Doss RW (2012). Cyclooxygenase-2 and prostaglandin E2 in vitiligo patients: plasma and tissue levels. Journal of the Egyptian Women's Dermatologic Society, 9 (2), 92-97.
Esmaeili B, Rezaee SA, Layegh P, Tavakkol Afshari J, Dye P, Ghayoor Karimiani E, Kalalinia F, Rafatpanah H (2011). Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol, 10 (2), 81–89.
Li M, Gao Y, Li C, Liu L, Li K, Gao L, Wang G, Zhang Z, Gao T (2009). Association of COX2 functional polymorphisms and the risk of vitiligo in Chinese populations. J Dermatol Sci, 53(3):176–81.
Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A (2002). Cyclooxygenase-2 promotes prostate cancer progression. Prostate, 53(3):232–40.
Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56(4):671–6.
Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25(2):229–35.
Daraei A, Salehi R, Mohamadhashem F (2012). PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep, 39(5):5219–24.
Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001). Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer, 91(6):894–9.
Oka A, Takashima S (1997). Induction of cyclo-oxygenase 2 in brains of patients with Down’s syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport, 8(5):1161–4.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ, 332(7553):1302–8.
Hippisley-Cox J, Coupland C (2005). Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ, 330(7504):1366.
Mukherjee D, Nissen SE, Topol EJ (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286(8):954–9.
Harris RE, Beebe-Donk J, Alshafie GA (2006). Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 6:27.
Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 62(3):632–5.
Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 59(5):991–4.
Ding XZ, Tong WG, Adrian TE (2000). Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res, 20(4):2625–31.
Cetin M, Buyukberber S, Demir M, Sari I, Sari I, Deniz K, Eser B, Altuntas F, Camci C, Oztürk A, Turgut B, Vural O, Unal A (2005). Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol, 80(3):169–73.
Trojan A, Tinguely M, Vallet S, Seifert B, Jenni B, Zippelius A, Witzens-Harig M, Mechtersheimer G, Ho A, Goldschmidt H, Jäger D, Boccadoro M, Ladetto M (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly, 136(25-26):400–3.
| Files | ||
| Issue | Vol 45 No 12 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Migraine COX-2 gene Polymorphism RFLP Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
